Article Figures & Data
Tables
Radiopharmaceutical Administered activity (MBq) Critical organ (bladder) Effective dose 99mTc-phosphates (intravenous) 500–1,110 0.047 (mGy/MBq) 0.0049 (mSv/MBq) 34.8 (mGy/740 MBq) 3.6 (mSv/740 MBq) 52.2 (mGy/1,110 MBq) 5.4 (mSv/1,110 MBq) Values for normal bone uptake and normal renal function are from Radiation Dose to Patients from Radiopharmaceuticals. London, U.K.: ICRP; 1988:215. ICRP report 53. See also Weber DA, Makler PT Jr, Watson EE, Coffey JL, Thomas SR, London J. MIRD dose estimate report no. 13: radiation absorbed dose from technetium-99m-labeled bone imaging agents. J Nucl Med. 1989;30:1117–1122.
Radiopharmaceutical Administered activity (MBq) Critical organ (bladder) Effective dose 99mTc-phosphates (intravenous) 170–210 0.11 (mGy/MBq) 0.012 (mSv/MBq) 18.7 (mGy/740 MBq) 2.0 (mSv/740 MBq) 23.1 (mGy/1,110 MBq) 2.5 (mSv/1,110 MBq) Values for normal bone uptake and normal renal function are from Radiation Dose to Patients from Radiopharmaceuticals. London, U.K.: ICRP; 1988:215. ICRP report 53. See also Weber DA, Makler PT Jr, Watson EE, Coffey JL, Thomas SR, London J. MIRD dose estimate report no. 13: radiation absorbed dose from technetium-99m-labeled bone imaging agents. J Nucl Med. 1989;30:1117–1122.
Jump to section
- Article
- I. INTRODUCTION
- II. GOALS
- III. DEFINITIONS
- IV. COMMON CLINICAL INDICATIONS
- V. QUALIFICATIONS AND RESPONSIBILITIES OF PERSONNEL
- VI. PROCEDURE/SPECIFICATIONS OF THE EXAMINATION
- VII. DOCUMENTATION/REPORTING
- VIII. EQUIPMENT SPECIFICATION
- IX. QUALITY CONTROL AND IMPROVEMENT
- X. SAFETY, INFECTION CONTROL, AND PATIENT EDUCATION CONCERNS
- XI. RADIATION SAFETY IN IMAGING
- XIV. APPROVAL
- Acknowledgments
- XIII. BIBLIOGRAPHY
- Figures & Data
- Info & Metrics